Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shrita M. Patel"'
Autor:
Tongtong Wang, Shrita M. Patel, Anne Hickman, Xinyue Liu, Philip LStJ Jones, Ira Gantz, Carol E. Koro
Publikováno v:
Diabetes Therapy, Vol 11, Iss 3, Pp 711-723 (2020)
Abstract Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of t
Externí odkaz:
https://doaj.org/article/57a78bad45474da09e6cb960c8bf56c0
Autor:
Steven Terra, Robert Frederich, Urszula Masiukiewicz, James P. Mancuso, Silvina Gallo, Brett Lauring, Shrita M. Patel, Mary A. Hickman, Susan Huyck, Susan L. Johnson
Publikováno v:
Diabetes. 67
Ertugliflozin (ERTU) is an SGLT2 inhibitor for the treatment of T2DM. The risk of fracture was assessed in adults with T2DM receiving ERTU relative to placebo (PBO) or active comparator in pooled analyses of 7 randomized, double-blind, Phase 3 trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c96a7e702050818c49d930ae9059054
https://doi.org/10.2337/db18-1145-p
https://doi.org/10.2337/db18-1145-p
Autor:
Robert Frederich, James P. Mancuso, Mary A. Hickman, Susan Huyck, Steven Terra, Shrita M. Patel, Susan L. Johnson, Brett Lauring
Publikováno v:
Diabetes. 67
Ertugliflozin (ERTU) is an SGLT2 inhibitor for the treatment of T2DM. Osmotic diuresis (OD), volume depletion (VD) and change in renal function were assessed in adults with T2DM. Pooled analyses were performed on data from 7 randomized, double blind,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dd60b057db3b2e8bb80d48c38e7e34e
https://doi.org/10.2337/db18-1169-p
https://doi.org/10.2337/db18-1169-p
Autor:
Steven Terra, Susan Huyck, James P. Mancuso, Shrita M. Patel, Brett Lauring, Robert Frederich, Susan L. Johnson, Mary A. Hickman
Publikováno v:
Diabetes. 67
Ertugliflozin (ERTU) is a SGLT2 inhibitor for the treatment of T2DM. Adverse renal effects were assessed in adults with T2DM receiving ERTU relative to placebo (PBO) or active comparators in pooled analyses of 7 randomized, double-blind, Phase 3 tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db878f8aab7869e87320ae97fbd4695a
https://doi.org/10.2337/db18-1168-p
https://doi.org/10.2337/db18-1168-p
Autor:
Nayyar Iqbal, Shailja Kaul, Arpita Basu, Anne R. Cappola, Sarah J. Ratcliffe, Theresa Scattergood, Michael R. Rickels, Shrita M. Patel, Muredach P. Reilly, Carissa Fuller
Publikováno v:
Fertility and Sterility. 94:2161-2166
Objective To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women. Design Randomized, double-blind, placebo-controlled study. Setting Clinical and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7f42020a7aef05ecbd55d39143f79c
https://doi.org/10.1016/j.fertnstert.2010.01.064
https://doi.org/10.1016/j.fertnstert.2010.01.064
Autor:
Shrita M. Patel, John E. Nestler
Publikováno v:
Endocrinology and Metabolism Clinics of North America. 35:137-155
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in the United States, affecting 5% to 10% of women of reproductive age. Several treatment options exist, including those that target insulin resistance. Once pregnan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b00ce9ed5aae5f8fcbfe638dac3bfa
https://doi.org/10.1016/j.ecl.2005.09.005
https://doi.org/10.1016/j.ecl.2005.09.005
Autor:
Marwan Badri, Debbie L. Cohen-Stein, Violeta Popii, Donald Yih, Ahmara V. Gibbons, Shrita M. Patel
Publikováno v:
Endocrine Practice. 19:e74-e76
Objective To describe the clinical course of a patient with a nonresectable pheochromocytoma during urgent hip surgery. Methods To describe the clinical management and postoperative outcome of the patient and review the relevant literature. Results A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::678053ef5c7b32e6443f694dc3993890
https://doi.org/10.4158/ep12343.cr
https://doi.org/10.4158/ep12343.cr
Autor:
Anne R. Cappola, Marc R. Blackman, Linda P. Fried, Muredach P. Reilly, Jane A. Cauley, Shrita M. Patel, John A Robbins, Sarah J. Ratcliffe, Rachel Weinstein, Kim Sutton-Tyrrell, Shalender Bhasin
Context: Early postmenopausal women with higher testosterone (T) levels have increased insulin resistance (IR) and cardiovascular risk factors, but whether this translates into increased cardiovascular disease later in life is unknown. Objective: The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::193d6bd6570aa0e6c45dc8fbb653b0ea
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 96:3599-3600
A 66-yr-old woman was referred to the National Institutes of Health for evaluation of tumor-induced osteomalacia. She had bone pain, fractures, and an elevated fibroblast growth factor 23 (FGF23) (2295 pg/ml; normal, 10–50). Fluorodeoxyglucose (FDG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05d43d31b908be5161a2695923b0118
https://doi.org/10.1210/jc.2011-1757
https://doi.org/10.1210/jc.2011-1757